What does capillary electrophoresis peptide purity determination report?
Capillary electrophoresis peptide purity determination reports how detector response is distributed among zones that separate in an electric field. The figure is a time-corrected area percentage. It is not milligrams of peptide in the vial, and it is not evidence of any biological action. The main zone is identified by migration time against a reference electropherogram, or by relative migration time against a neutral or charged marker, before its corrected area is compared with other integrated zones.
Free-solution capillary electrophoresis was shown to separate proteins and peptides at analytical scale as the technique matured (PMID:2757205). Later reviews of peptide capillary electrophoresis and capillary electrochromatography catalogue the practical variables that decide whether a deletion sequence, a truncation or a deamidated form appears as its own zone: background-electrolyte pH, ionic strength, wall coating, temperature and detection (PMID:11824634; PMID:14661232; PMID:16307429). A status review of capillary electrophoresis in pharmaceutical analysis supports treating CE as a defined laboratory method rather than an informal screen (PMID:10596827).
The percentage is only meaningful inside the method that produced it. The protocol should define the reporting threshold, whether the electroosmotic-flow disturbance is excluded from the sum, and whether purity means main-zone corrected-area percent or the sum of specified impurities. Low-pH bare-silica CZE and a coated capillary near neutral pH will not resolve the same critical pair. Those two percentages must not be averaged. For an Australian research lot, the interpretable package is the electropherogram, the method identifier, the integration rule and the lot number, read next to the orthogonal HPLC or mass-spectrometric identity record. A standalone percentage with none of those fields cannot be reviewed.
How does capillary zone electrophoresis separate peptide-related substances?
Apparent mobility is calculated as mu_app = L_d x L_t / (V x t_m), with L_d the length to the detector, L_t the total capillary length, V the voltage and t_m the migration time. Effective mobility is apparent mobility minus the electroosmotic mobility of a neutral marker. Net charge at the background-electrolyte pH, set against the peptide isoelectric point and the pKa values of the termini and side chains, dominates that effective mobility. A deamidation that converts Asn or Gln to a carboxylic acid adds negative charge and often moves the zone even when reversed-phase retention barely changes. That charge selectivity is why CZE is kept as an orthogonal purity method beside HPLC.
The capillary wall is a method parameter. Ionised silanols at moderate or high pH create cathodic electroosmotic flow and adsorb basic peptides, which broadens zones and can depress the main-peak area. Low-pH electrolytes protonate silanols, suppress flow and limit adsorption, but they lengthen the run and can fail a critical pair. Coatings are then a documented alternative. Peptide CE and isoelectric-focusing reviews treat wall chemistry as part of selectivity and precision, not as optional hardware (PMID:16307429; PMID:23180512).
Joule heating sets the upper voltage. Current increases with ionic strength; if heat is not removed, the centre of the lumen is less viscous, the flow bows and efficiency falls. Electromigration dispersion appears when analyte mobility differs strongly from the background co-ion, so the zone front or tail hides a minor related substance. Lock voltage, current, internal diameter, thermostat setpoint and electrolyte conductivity in the protocol. Set resolution and migration-time repeatability before the sequence starts. Those values are batch-record fields, not after-the-fact comments.
Why is time-corrected peak area required for a CE purity percentage?
In chromatography, analytes travel through the detector at nearly the same velocity, so raw area is a fair response comparison if the chromophore is similar. In CE, each zone passes the detection window at its own velocity. A slower zone dwells longer and accumulates more area even when the amount is the same. Corrected area is raw area divided by migration time. Purity is then 100 times the main-zone corrected area divided by the sum of corrected areas of peaks at or above the reporting threshold. Using raw area systematically overstates late zones and understates early ones.
The calculation still assumes comparable absorptivity at the reporting wavelength. Peptide-bond absorbance near 200 to 214 nm is the usual channel because many related substances lack Trp or Tyr and are invisible at 280 nm. A non-peptide counter-ion, a residual protecting group with a different chromophore, or a wavelength chosen only for the main component will distort area percent. State the wavelength and bandwidth on the report. If 214 nm and 280 nm are both collected, do not blend them into one purity number; keep a channel-specific table.
Corrected-area percent is not net peptide content. Water, acetate, trifluoroacetate and residual solvent add mass and usually add little response at the peptide wavelength, so a high CE percentage can sit beside a much lower mass fraction. Counter-ion content has been measured by capillary zone electrophoresis and capillary isotachophoresis alongside purity degree for the synthetic peptide lecirelin (PMID:16687256). Those rows stay separate on a certificate of analysis. An internal standard corrects introduction volume; it does not replace time correction, and it is excluded from the purity sum.
When should on-line preconcentration or isotachophoresis be used?
The optical path in a 50 micrometre capillary is about the internal diameter, so concentration sensitivity is weaker than in a conventional HPLC flow cell. A minor related substance can sit in the noise while the main zone is already triangular from overload. On-line preconcentration raises the amount that reaches the detector without an offline step that might alter the impurity profile. Field-amplified stacking uses a low-conductivity sample plug: the field inside the plug is higher, and analytes slow at the boundary with the background electrolyte. Transient isotachophoresis stacks analytes between a leading ion and a terminating ion before zone electrophoresis starts.
On-line preconcentration has been used to monitor synthetic-peptide purity, with the analytical aim of clearer separation and higher detection sensitivity (PMID:11315150). A review of on-line preconcentration for proteins and peptides covers stacking and related focusing modes (PMID:11519939). If the specification includes impurities near the reporting threshold, the method file must state whether stacking was used, because peak height and sometimes resolution change relative to a sample dissolved in background electrolyte.
Capillary isotachophoresis can also quantify directly: fully developed zone length is proportional to amount. That measurement has been paired with CZE to report purity degree and counter-ion content for lecirelin (PMID:16687256). For an acetate or trifluoroacetate research salt, a separate counter-ion result prevents the purity electropherogram being read as a mass fraction. Indirect ultraviolet detection is the usual readout when the counter-ion itself has no useful chromophore. The certificate should name the introduction mode, whether hydrodynamic pressure-time, electrokinetic voltage-time or a stacking programme, because lot comparison is valid only when the mode matches.
How do gel electrophoresis and isoelectric focusing differ from CZE?
Free-solution CZE barely sieves. Peptides of similar charge-to-size ratio co-migrate even when one is a truncation, unless the charge difference shifts mobility. Capillary gel electrophoresis adds a polymer network that retards larger species. It has been applied to quantification and purity determination of recombinant proteins from inclusion bodies, where fragments and the target differ in size and processing (PMID:23857606). For a short synthetic peptide the sieving gain is often small, so a gel method is the wrong default. It is relevant for longer chains, disulphide-linked dimers, or lots where truncation and aggregation are specified impurities and CZE has already shown co-migration.
Isoelectric focusing separates by isoelectric point in a pH gradient, not by mobility at one pH. Capillary electrophoresis and isoelectric focusing are complementary for peptides and proteins (PMID:23180512). Deamidation can shift pI even when a background electrolyte far from both isoelectric points barely moves the CZE zone. Controls are an ampholyte blank, a check for anodic or cathodic drift, and evidence that the zone had stopped moving. Short peptides diffuse quickly; a broad focused zone is not automatically a second component.
Capillary electrochromatography is the hybrid: electroosmotic flow drives liquid through a stationary phase while charged solutes still migrate electrophoretically. Peptide work in that mode is reviewed with peptide CE (PMID:14661232; PMID:16307429). Reserve it for a critical pair unresolved by both reversed-phase HPLC and CZE, and name the phase on the report. The resulting percentage is neither a pure mobility figure nor an HPLC area percent. Across all four modes, a CE purity figure without the mode name is not a reviewable result.
How should an Australian laboratory file a CE purity result beside HPLC?
CE and HPLC do not measure the same selectivity. Engineered Cas9 has been characterised with both UHPLC-based and CE-based methods in one analytical programme (PMID:35988299). CE purity assessment has also been applied to a nanobody, so charge-based profiling is not restricted to very large proteins (PMID:24626396). The same reading rule fits a synthetic research peptide: reversed-phase area percent may look simple while CZE shows a charge variant, or the reverse. Disagreement is a result. It is not settled by publishing the higher percentage.
A reviewable Australian file links lot number, electropherogram sample name, method version and data-file identifier. Required instrument fields are capillary dimensions and coating, background-electrolyte identity and measured pH, voltage and polarity, thermostat setpoint, detection wavelength, introduction mode, and the corrected-area rule with its reporting threshold. System suitability in the same sequence covers migration-time repeatability, current stability and resolution from the nearest specified related substance. An unidentified zone stays unknown; it is not given an HPLC relative-retention label unless mass data justify the link.
Migration time does not confirm sequence. Intact mass or tandem mass spectrometry does; CE does not. Pharmaceutical CE practice already expects a defined method and an impurity context (PMID:10596827). Australian research-use supply should copy that documentation standard without medicine-style labelling. When a buyer compares suppliers, the questions are whether purity is HPLC area percent, CE corrected-area percent or both, and whether water and counter-ion are reported so net content is not inferred from the electropherogram. ClaraScience files these as research analytical records. A CE figure on a research peptide is not a human-use recommendation.
Frequently asked questions
Is capillary electrophoresis peptide purity the same as HPLC purity?
No. HPLC area percent reflects hydrophobic retention under a stated gradient. CE corrected-area percent reflects mobility at a stated pH, voltage and wall condition. A lot can pass one and show an extra zone on the other. Report both with their method identifiers. Do not average them, and do not treat either figure as net peptide content or as a human-use specification.
Why divide peak area by migration time?
Because each zone crosses the detection window at its own speed. A later zone spends longer in the window and gains raw area even when the amount is unchanged. Dividing raw area by migration time removes that dwell-time bias before the purity percentage is calculated. An internal standard can correct how much sample was introduced. It does not replace the time correction. Exclude the standard from the purity sum.
Can CE measure acetate or trifluoroacetate as well as peptide purity?
Yes, but usually as a separate method. Peptide purity is typically a direct ultraviolet corrected-area percent. Acetate and trifluoroacetate often need indirect ultraviolet CZE or capillary isotachophoresis, where zone length or indirect response tracks the ion. Lecirelin purity degree and counter-ion content have been determined that way by CZE and CITP (PMID:16687256). Keep the ion result on its own certificate row so it is not folded into the peptide percentage without a stated mass-balance calculation.
Does a single CE peak prove the peptide sequence?
No. Co-migration of similar charge-to-size species is a known CZE limitation, and migration time is a method-dependent identifier, not a sequence. Identity requires mass spectrometry, with tandem fragmentation where the lot specification calls for it. CE remains useful because a charge variant that co-elutes on one reversed-phase method can still appear as a second zone. File the electropherogram beside the mass spectrum rather than instead of it.
What should be on the certificate if CE is the purity method?
Name the mode, whether CZE, gel electrophoresis, isoelectric focusing or electrochromatography. Also record capillary dimensions and coating, background electrolyte and pH, voltage, temperature setpoint, wavelength, introduction mode and the corrected-area threshold. Attach or cross-reference the electropherogram and the system-suitability result for that sequence. State that the figure is not net content. For Australian research procurement, those fields are what make one supplier percentage comparable with another lot.
Are research-peptide CE results a finished-product quality standard?
No. The techniques overlap with methods used in pharmaceutical analysis, including defined impurity methods (PMID:10596827), but a research-lot electropherogram does not authorise human use and is not a finished-product release. Read it as laboratory characterisation of charge-based purity and, where reported, counter-ion content, beside a separate identity test. Specifications are those written in the research method. They are not implied human-use limits.
References
- PMID:2757205 — Application of free-solution capillary electrophoresis to the analytical scale separation of proteins and peptides — Anal Chem — 1989
- PMID:11824634 — Recent advances in capillary electrophoresis of peptides — Electrophoresis — 2001
- PMID:14661232 — Recent advances in capillary electrophoresis and capillary electrochromatography of peptides — Electrophoresis — 2003
- PMID:16307429 — Recent developments in capillary electrophoresis and capillary electrochromatography of peptides — Electrophoresis — 2006
- PMID:10596827 — Capillary electrophoresis of drugs: current status in the analysis of pharmaceuticals — Electrophoresis — 1999
- PMID:23180512 — Capillary electrophoresis and isoelectric focusing in peptide and protein analysis — Proteomics — 2013
- PMID:16687256 — Determination of purity degree and counter-ion content in lecirelin by capillary zone electrophoresis and capillary isotachophoresis — J Chromatogr B Analyt Technol Biomed Life Sci — 2006
- PMID:11315150 — Monitoring the purity of a synthetic peptide by capillary electrophoresis: utilization of an on-line preconcentration method for improved separation and detection sensitivity — J Capill Electrophor Microchip Technol — 1999
- PMID:11519939 — On-line sample preconcentration in capillary electrophoresis, focused on the determination of proteins and peptides — Electrophoresis — 2001
- PMID:23857606 — Capillary gel electrophoresis for the quantification and purity determination of recombinant proteins in inclusion bodies — Electrophoresis — 2013
- PMID:35988299 — Comprehensive UHPLC- and CE-based methods for engineered Cas9 characterization — Talanta — 2023
- PMID:24626396 — Capillary electrophoresis-based assessment of nanobody affinity and purity — Anal Chim Acta — 2014
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
